Synapse - GDMT, Medicine

Results (1898)

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)

Meeting Abstract

Kwan, T.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A. P.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)

Meeting Abstract

Grisham, R. N.; Vergote, I.; Banerjee, S. N.; Drill, E. N.; Fabbro, M.; Mirza, M. R.; Romero, I.; Coleman, R. L.; Oza, A. M.; Hilpert, F.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC)

Meeting Abstract

Lorusso, D.; Colombo, N.; Herraez, A. C.; Santin, A.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors - Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort

Meeting Abstract

Hamilton, E. P.; Jackson, C. C.; Eskander, R. N.; Backes, F. J.; Makker, V.; Musa, F.; Olawaiye, A.; Alldredge, J.; Pothuri, B.; Secord, A. A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)

Meeting Abstract

Banerjee, S. N.; Monk, B. J.; Van Nieuwenhuysen, E.; Moore, K. N.; Oaknin, A.; Fabbro, M.; Colombo, N.; O'Malley, D. M.; Coleman, R. L.; Pachter, J. A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study

Meeting Abstract

Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Liu, Y. L.; Provencher, D. M.; McCormick, C.; ElNaggar, A.; Altman, A. D.; Gilbert, L.; Black, D.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors

Meeting Abstract

Meric-Bernstam, F.; Hainsworth, J.; Bose, R.; Burris, H. A. 3rd; Friedman, C. F.; Kurzrock, R.; Swanton, C.; Wang, Y.; Levy, J.; Schulze, K.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Determination of clinical benefit among patients with radiological stable disease to immune checkpoint inhibitors

Meeting Abstract

Luo, J.; Wu, S.; Rizvi, H.; Zhang, Q.; Egger, J. V.; Osorio, J. C.; Schoenfeld, A. J.; Plodkowski, A. J.; Ginsberg, M. S.; Gupta, A. K.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS)

Meeting Abstract

Crowley, F.; Cadoo, K. A.; Chiang, S.; Mueller, J. J.; Hensley, M. L.; O'Cearbhaill, R. E.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection

Meeting Abstract

Lumish, M. A.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z. K.; Ku, G. Y.; Segal, N. H.; Won, E.; Maron, S. B.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save